Compare Regeneron Pharmaceuticals Inc (REGN) vs Ulta Beauty Inc (ULTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Ulta Beauty Inc — how do they compare? Regeneron Pharmaceuticals Inc trades at $652.76 (market cap $70.79B), while Ulta Beauty Inc trades at $480 (market cap $21.04B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 3.4× Ulta Beauty Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.56% dividend while Ulta Beauty Inc pays none. Which is the better fit depends on your goals.
| REGN | ULTA | |
|---|---|---|
Market Cap | $70.79B | $21.04B |
Sector | Health | Consumer Cyclical |
52-Week High | $812.27 | $706.82 |
52-Week Low | $545.46 | $450.75 |
Enterprise Value | $64.74B | $23.12B |
Dividend Yield | 0.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
ULTA Beauty trades at $489.47, up 2.06% with a bullish technical signal despite mixed moving averages. The company maintains strong profitability with 39.33% gross margins and 47.45% ROE, though net margins have declined from 12.17% in 2023 to 10.63% in 2025. Recent Q1 2026 earnings beat expectations at $7.74 EPS versus $6.89 expected, while Q4 2025 missed. Analyst consensus remains strongly positive with 26 buy ratings and a $618.29 price target, representing 26% upside potential.
ULTA presents a compelling growth story with international expansion and digital engagement driving long-term potential. However, investors face risks from margin compression, competitive pressures in beauty retail, and volatile cash flow patterns. The stock's current valuation at 18.29x P/E appears reasonable given growth prospects, but requires monitoring of consumer spending trends and execution on strategic initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Ulta Beauty Inc
With more than 1,300 stores and a partnership with Target, Ulta Beauty is the largest specialized beauty retailer in the U.S. The firm offers makeup (43% of 2021 sales), fragrances, skin care, and hair care products (20% of 2021 sales), and bath and body items. Ulta offers private-label products and merchandise from more than 500 vendors. It also offers salon services, including hair, makeup, skin, and brow services, in all stores. Most Ulta stores are approximately 10,000 square feet and are in suburban strip centers. Ulta was founded in 1990 and is based in Bolingbrook, Illinois.
Read more on ULTA →
